Effects of soy consumption on serum lipids and apoproteins in peritoneal dialysis patients: A randomized controlled trial

Peritoneal Dialysis International

Volumn 30, Issue 6, 2010, Pages 611-618

  Tabibi, Hadi ^a   Imani, Hossein ^a   Hedayati, Mehdi ^b   Atabak, Shahnaz ^b   Rahmani, Leila ^c  

^a National Nutrition and Food Technology Research Institute Tehran   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Apoproteins; Lipoprotein(a); Serum lipids; Soy

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN B100; APOLIPOPROTEIN LP; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED STUDY; DIETARY INTAKE; FEEDING BEHAVIOR; FEMALE; FOOD INTAKE; HUMAN; MALE; PATIENT COMPLIANCE; PERITONEAL DIALYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SOYBEAN; TRIACYLGLYCEROL BLOOD LEVEL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; APOLIPOPROTEIN A-I; APOLIPOPROTEIN B-100; APOPROTEINS; BODY MASS INDEX; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIETARY PROTEINS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIPIDS; LIPOPROTEIN(A); MALE; MEDICAL RECORDS; MIDDLE AGED; PERITONEAL DIALYSIS; SOY FOODS; SOYBEAN PROTEINS; TRIGLYCERIDES; YOUNG ADULT;

EID: 78650090184     PISSN: 08968608     EISSN: 17184304     Source Type: Journal    
DOI: 10.3747/pdi.2009.00161     Document Type: Article

References (42)

1. Singh AK, Brenner BM. Dialysis in the treatment of renal failure. In: Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL, eds. Harrison's Principles of Internal Medicine. 16th ed. New York: McGraw-Hill; 2005: 1663-7.
2. Jungers P, Nquyen Khoa T, Massy ZA, Zingraff J, Labrunie M, Descamps-Latscha B, et al. Incidence of atherosclerotic arterial occlusive accidents in predialysis and dialysis patients: a multicentric study in the Ile de France district. Nephrol Dial Transplant 1999; 14:898-902.
3. Wanner C. Altered lipid metabolism and serum lipids in renal disease and renal failure. In: Kopple JD, Massary SG, eds. Kopple and Massary's Nutritional Management of Renal Disease. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2004: 42-55.
4. O'Neal D, Lee P, Murphy B, Best J. Low-density lipoprotein particle size distribution in end-stage renal disease treated with hemodialysis or peritoneal dialysis. Am J Kidney Dis 1996; 27:84-91.
5. Shoji T, Nishizawa Y, Nishitani H, Yamakawa M, Morii H. High serum lipoprotein(a) concentrations in uremic patients treated with continuous ambulatory peritoneal dialysis. Clin Nephrol 1992; 38:271-6.
6. Fytili CI, Progia EG, Panagoutsos SA, Thodis ED, Passadakis PS, Sombolos KI, et al. Lipoprotein abnormalities in hemodialysis and continuous ambulatory peritoneal dialysis patients. Ren Fail 2002; 24:623-30.
7. Kimak E, Berger B, Solski J, Janicka L, Ksiazek A. Comparison of lipid and lipoprotein profiles in long-term chronic ambulatory peritoneal dialysis (CAPD) in elderly patients with chronic renal failure (CRF). Int Urol Nephrol 2002; 33:203-4.
8. Ong-Ajyooth L, Sirisalee K, Shayakul C, Vareesangthip K, Vasuvattakul S, Vanichakarn S, et al. Comparison of lipid abnormalities in continuous ambulatory peritoneal dialysis and hemodialysis patients. Transplant Proc 1994; 26: 2077-9.
9. Siamopoulos KC, Elisaf MS, Bairaktari HT, Pappas MB, Sferopoulos GD, Nikolakakis NG. Lipid parameters including lipoprotein (a) in patients undergoing CAPD and hemodialysis [Abstract]. Perit Dial Int 1995; 15:342-7.
10. Garcia-Lopez E, Carrero JJ, Suliman ME, Lindholm B, Stenvinkel P. Risk factors for cardiovascular disease in patients undergoing peritoneal dialysis. Perit Dial Int 2007; 27(Suppl 2):S205-9.
11. Superko HR. Did grandma give you heart disease? The new battle against coronary artery disease. Am J Cardiol 1998; 82:34Q-46Q.
12. Spinler SA, Cziraky MJ. Lipoprotein(a): physiologic function, association with atherosclerosis, and effects of lipidlowering drug therapy. Ann Pharmacother 1994; 28: 343-51.
13. Djurovic S, Berg K. Epidemiology of Lp(a) lipoprotein: its role in atherosclerotic/thrombotic disease. Clin Genet 1997; 52:281-92.
14. Dahlen GH, Stenlund H. Lp(a) lipoprotein is a major risk factor for cardiovascular disease: pathogenic mechanisms and clinical significance. Clin Genet 1997; 52:272-80.
15. Heimburger O, Stenvinkel P, Berglund L, Tranaeus A, Lindholm B. Increased plasma lipoprotein(a) in continuous ambulatory peritoneal dialysis is related to peritoneal transport of proteins and glucose. Nephron 1996; 72: 135-44.
16. Wong WW, Smith EO, Stuff JE, Hachey DL, Heird WC, Pownell HJ. Cholesterol-lowering effect of soy protein in normocholesterolemic and hypercholesterolemic men. Am J Clin Nutr 1998; 68(6 Suppl):1385S-9S.
17. Lichtenstein AH, Jalbert SM, Adlercreutz H, Goldin BR, Rasmussen H, Schaefer EJ, et al. Lipoprotein response to diets high in soy or animal protein with and without isoflavones in moderately hypercholesterolemic subjects. Arterioscler Thromb Vasc Biol 2002; 22:1852-8.
18. Tonstad S, Smerud K, Hoie L. A comparison of the effects of 2 doses of soy protein or casein on serum lipids, serum lipoproteins, and plasma total homocysteine in hypercholesterolemic subjects. Am J Clin Nutr 2002; 76:78-84.
19. Jenkins DJ, Kendall CWC, Jackson CJ, Connelly PW, Parker T, Faulkner D, et al. Effects of high- and low-isoflavone soyfoods on blood lipids, oxidized LDL, homocysteine, and blood pressure in hyperlipidemic men and women. Am J Clin Nutr 2002; 76:365-72.
20. Teixeira SR, Potter SM, Weigel R, Hannum S, Erdman JW Jr, Hasler CM. Effects of feeding 4 levels of soy protein for 3 and 6 wk on blood lipids and apolipoproteins in moderately hypercholesterolemic men. Am J Clin Nutr 2000; 71: 1077-84.
21. Desroches S, Mauger JF, Ausman LM, Lichtenstein AH, Larmarche B. Soy protein favorably affects LDL size independently of isoflavones in hypercholesterolemic men and women. J Nutr 2004; 134:574-9.
22. Nilausen K, Meinertz H. Lipoprotein(a) and dietary proteins: casein lowers lipoprotein(a) concentration as compared with soy protein. Am J Clin Nutr 1999; 69:419-25.
23. Hoie LH, Morgenstern ECA, Gruenwald J, Graubaum HJ, Busch R, Luder W, et al. A double-blind placebo-controlled clinical trial compares the cholesterol-lowering effects of two different soy protein preparations in hypercholesterolemic subjects. Eur J Nutr 2005; 44:65-71.
24. Wang Y, Jones PJH, Ausman LM, Lichtenstein AH. Soy protein reduces triglyceride levels and triglyceride fatty acid fractional synthesis rate in hypercholesterolemic subjects. Atherosclerosis 2004; 173:269-75.
25. Anderson JW, Johnstone BM, Cook-Newell ME. Metaanalysis of the effects of soy protein intake on serum lipids. N Engl J Med 1995; 333:276-82.
26. Weggemans RM, Trautwein EA. Relation between soyassociated isoflavones and LDL and HDL cholesterol concentrations in humans: a meta-analysis. Eur J Clin Nutr 2003; 57:940-6.
27. Dent SB, Peterson CT, Brace LD, Swain JH, Reddy MB, Hanson KB, et al. Soy protein intake by perimenopausal women does not affect circulating lipids and lipoproteins or coagulation and fibrinolytic factors. J Nutr 2001; 131: 2280-7.
28. Meinertz H, Nilausen K, Hilden J. Alcohol-extracted, but not intact, dietary soy protein lowers lipoprotein(a) markedly. Arterioscler Thromb Vasc Biol 2002; 22:312-16.
29. Lacour B, Massy Z, Drueke TB. Lipid metabolism. In: Massry SG, Glassock RJ, eds. Massry & Glassock's Textbook of Nephrology. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2001: 1346-56.
30. Ross EA, Shah GM, Kashyap ML. Elevated plasma lipoprotein (a) levels and hypoalbuminemia in peritoneal dialysis patients. Int J Artif Organs 1995; 18:751-6.
31. Anwar N, Bhatnagar D, Short CD, Mackness MI, Durrington PN, Prais H, et al. Serum lipoprotein (a) concentrations in patients undergoing continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 1993; 8:71-4.
32. Irish AB, Simons LA, Savdie E, Hayes JM, Simons J. Lipoprotein(a) levels in chronic renal disease states, dialysis and transplantation [Abstract]. Aust N Z J Med 1992; 22: 243-8.
33. Yang WS, Kim SB, Min WK, Park S, Lee MS, Park JS. Atherogenic lipid profile and lipoprotein(a) in relation to serum albumin in haemodialysis patients [Abstract]. Nephrol Dial Transplant 1995; 10:1668-71.
34. Scanu AM. Atherothrombogenicity of lipoprotein(a): the debate. Am J Cardiol 1998; 82:26Q-33Q.
35. Huang Y, Cao S, Nagamani M, Anderson KE, Grady JJ, Lu LJ. Decreased circulating levels of tumor necrosis factoralpha in postmenopausal women during consumption of soy-containing isoflavones. J Clin Endocrinol Metab 2005; 90:3956-62.
36. Olyaei AJ, Demattos AM, Bennett WM. Prescribing drugs in renal disease. In: Brenner BM, ed. Brenner & Rector's the Kidney. 6th ed. Philadelphia: W.B. Saunders; 2000: 2632-4.
37. Engelman HM, Alekel DL, Hanson LN, Kanthasamy AG, Reddy MB. Blood lipid and oxidative stress responses to soy protein with isoflavones and phytic acid in postmenopausal women. Am J Clin Nutr 2005; 81:590-6.
38. Chen ST, Ferng SH, Yang CS, Peng SJ, Lee HR, Chen JR. Variable effects of soy protein on plasma lipids in hyperlipidemic and normolipidemic hemodialysis patients. Am J Kidney Dis 2005; 46:1099-106.
39. Prichard SS. Metabolic complications of peritoneal dialysis. In: Daugirdas JT, Blake PG, Ing TS, eds. Handbook of Dialysis. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2001: 405-10.
40. Chen ST, Chen JR, Yang CS, Peng SJ, Ferng SH. Effect of soya protein on serum lipid profile and lipoprotein concentrations in patients undergoing hypercholesterolaemic haemodialysis. Br J Nutr 2006; 95:366-71.
41. Taku K, Umegaki K, Sato Y, Taki Y, Endoh K, Watanabe S. Soy isoflavones lower serum total and LDL cholesterol in humans: a meta-analysis of 11 randomized controlled trials. Am J Clin Nutr 2007; 85:1148-56.
42. Allen JK, Becker DM, Kwiterovich PO, Lindenstruth KA, Curtis C. Effect of soy protein-containing isoflavones on lipoproteins in postmenopausal women. Menopause 2007; 14:106-14.